Zenlabs Ethica Limited (BOM:530697)

Market Cap	192.05M -9.1%
Revenue (ttm)	493.24M -8.3%
Net Income	-18.46M
EPS	-2.88
Shares Out	6.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,494
Average Volume	14,770
Open	28.95
Previous Close	28.83
Day's Range	28.95 - 32.50
52-Week Range	16.50 - 39.20
Beta	-0.39
RSI	69.79
Earnings Date	May 19, 2026

About Zenlabs Ethica

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530697

Financial Performance

In fiscal year 2025, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.